The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and laboratory outcomes of all the participants enrolled in the study will be evaluated at the end of the study to explore if there is any difference in the outcomes between 2 groups.

开始日期2020-10-21

申办/合作机构

Rutgers State University of New Jersey

[+1]

NCT04360720

/ Recruiting临床3期IIT

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System in Brazil

Phase-3, randomized, multicenter, parallel-group study with blind evaluation of endpoints and intention-to-treat analysis.
The general purpose of the study is evaluate the non-inferiority hypothesis for ischemic events and the superiority hypothesis for bleeding events resulting from platelet P2Y12 receptor inhibitors given as monotherapy in comparison with conventional dual antiplatelet therapy in acute coronary syndrome patients treated with percutaneous coronary intervention in the context of the Unified Health System in Brazil.

开始日期2020-10-15

申办/合作机构

Hospital Israelita Albert Einstein

NCT01781611

/ TerminatedN/AIIT

Dipyridamole Assessment for Flare Reduction in SLE

Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice with lupus. The investigators are interested in investigating the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on biomarkers of disease activity.

开始日期2013-02-01

申办/合作机构

Oklahoma Medical Research Foundation

100 项与阿司匹林/双嘧达莫相关的临床结果

登录后查看更多信息

100 项与阿司匹林/双嘧达莫相关的转化医学

登录后查看更多信息

100 项与阿司匹林/双嘧达莫相关的专利（医药）

登录后查看更多信息

项与阿司匹林/双嘧达莫相关的文献（医药）

2019-01-11·Pain Physician3区 · 医学

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines

3区 · 医学

Review

作者: Laxmaiah Manchikanti ; Douglas Beall ; Sairam Atluri ; Cyrus Bakhit ; Salahadin Abdi ; Hari Prabhakar ; Alan D. Kaye ; Richard E. Latchaw ; Richard D. Urman ; Kenneth D. Candido ; Ramsin M. Benyamin ; Jay S. Grider ; Mark R. Jones ; Matthew B. Novitch ; Nebojsa Nick Knezevic ; Sudhir Diwan ; Erik M. Helander ; Ricardo Vallejo ; Elyse M. Cornett ; Amol Soin ; Thomas T. Simopoulos ; Michael E. Harned ; Joshua A. Hirsch ; Mahendra Sanapati ; Timothy R. Deer ; Matthew R. Eng ; Imran N. Mungrue ; John R. Swicegood ; Muhammad Anwar ; Sheri L. Albers ; Ramarao Pasupuleti

Background: Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in interventional pain are medicated using anticoagulant or antithrombotic drugs to mitigate thrombosis risk. Since these drugs target the clotting system, bleeding risk is a consideration accompanying interventional procedures. Importantly, discontinuation of anticoagulant or antithrombotic drugs exposes underlying thrombosis risk, which can lead to significant morbidity and mortality especially in those with coronary artery or cerebrovascular disease. This review summarizes the literature and provides guidelines based on best evidence for patients receiving anti-clotting therapy during interventional pain procedures. Study Design: Best evidence synthesis. Objective: To provide a current and concise appraisal of the literature regarding an assessment of the bleeding risk during interventional techniques for patients taking anticoagulant and/or antithrombotic medications. Methods: A review of the available literature published on bleeding risk during interventional pain procedures, practice patterns and perioperative management of anticoagulant and antithrombotic therapy was conducted. Data sources included relevant literature identified through searches of EMBASE and PubMed from 1966 through August 2018 and manual searches of the bibliographies of known primary and review articles. Results: 1. There is good evidence for risk stratification by categorizing multiple interventional techniques into low-risk, moderate-risk, and high-risk. Also, their risk should be upgraded based on other risk factors. 2. There is good evidence for the risk of thromboembolic events in patients who interrupt antithrombotic therapy. 3. There is good evidence supporting discontinuation of low dose aspirin for high risk and moderate risk procedures for at least 3 days, and there is moderate evidence that these may be continued for low risk or some intermediate risk procedures.4. There is good evidence that discontinuation of anticoagulant therapy with warfarin, heparin, dabigatran (Pradaxa®), argatroban (Acova®), bivalirudin (Angiomax®), lepirudin (Refludan®), desirudin (Iprivask®), hirudin, apixaban (Eliquis®), rivaroxaban (Xarelto®), edoxaban (Savaysa®, Lixiana®), Betrixaban(Bevyxxa®), fondaparinux (Arixtra®) prior to interventional techniques with individual consideration of pharmacokinetics and pharmacodynamics of the drugs and individual risk factors increases safety. 5. There is good evidence that diagnosis of epidural hematoma is based on severe pain at the site of the injection, rapid neurological deterioration, and MRI with surgical decompression with progressive neurological dysfunction to avoid neurological sequelae. 6. There is good evidence that if thromboembolic risk is high, low molecular weight heparin bridge therapy can be instituted during cessation of the anticoagulant, and the low molecular weight heparin can be discontinued 24 hours before the pain procedure. 7. There is fair evidence that the risk of thromboembolic events is higher than that of epidural hematoma formation with the interruption of antiplatelet therapy preceding interventional techniques, though both risks are significant. 8. There is fair evidence that multiple variables including anatomic pathology with spinal stenosis and ankylosing spondylitis; high risk procedures and moderate risk procedures combined with anatomic risk factors; bleeding observed during the procedure, and multiple attempts during the procedures increase the risk for bleeding complications and epidural hematoma. 9. There is fair evidence that discontinuation of phosphodiesterase inhibitors is optional (dipyridamole [Persantine], cilostazol [Pletal]. However, there is also fair evidence to discontinue Aggrenox [dipyridamole plus aspirin]) 3 days prior to undergoing interventional techniques of moderate and high risk. 10. There is fair evidence to make shared decision making between the patient and the treating physicians with the treating physician and to consider all the appropriate risks associated with continuation or discontinuation of antithrombotic or anticoagulant therapy. 11. There is fair evidence that if thromboembolic risk is high antithrombotic therapy may be resumed 12 hours after the interventional procedure is performed. 12. There is limited evidence that discontinuation of antiplatelet therapy (clopidogrel [Plavix®], ticlopidine [Ticlid®], Ticagrelor [Brilinta®] and prasugrel [Effient®]) avoids complications of significant bleeding and epidural hematomas. 13. There is very limited evidence supporting the continuation or discontinuation of most NSAIDs, excluding aspirin, for 1 to 2 days and some 4 to 10 days, since these are utilized for pain management without cardiac or cerebral protective effect. Limitations: The continued paucity of the literature with discordant recommendations. Conclusion: Based on the survey of current literature, and published clinical guidelines, recommendations for patients presenting with ongoing antithrombotic therapy prior to interventional techniques are variable, and are based on comprehensive analysis of each patient and the risk-benefit analysis of intervention. Key words: Perioperative bleeding, bleeding risk, practice patterns, anticoagulant therapy, antithrombotic therapy, interventional techniques, safety precautions, pain

2019-01-01·Journal of Thrombosis and Haemostasis2区 · 医学

Preventing arteriovenous shunt failure in hemodialysis patients: a population‐based cohort study

2区 · 医学

Article

作者: Chang, T-Y ; Liu, S H ; Kuo, C F ; Tian, Y C ; Lee, C C ; Li, I-J ; Fan, P Y ; Wu, H H ; Tu, K H ; Yang, C W ; Weng, C H ; Hsieh, M Y

Essentials Uncertainty remains about antiplatelets for vascular access patency in hemodialysis patients. 95 971 people under hemodialysis were followed in a claims database in Taiwan. Aspirin reduced vascular access failure rate and did not increase major bleeding rate. Clopidogrel, Aggrenox, and warfarin might increase major bleeding rate. SUMMARY: Background Dialysis adequacy is a major determinant of survival for patients with end-stage renal disease. Good vascular access is essential to achieve adequate dialysis. Objectives This study evaluated the impacts of different drugs on the vascular access failure rate of an arteriovenous fistula or an arteriovenous graft and the rate of major bleeding in hemodialysis patients. Patients and methods We studied patients with end-stage renal disease registered in the Taiwan National Health Insurance program from 1 January 1997 to 31 December 2012. A total of 95 971 patients were enrolled in our study. Vascular access dysfunction was defined as the need for thrombectomy or percutaneous angioplasty. Major bleeding was defined as emergency department visits or hospitalization with a primary diagnosis of gastrointestinal bleeding or intracerebral hemorrhage. The adjusted odds ratios between person-quarters with or without antiplatelet or oral anticoagulant use were calculated using a generalized estimating equation. Results The odds ratio of vascular access failure was 0.21 (0.11-0.39) for aspirin, 0.76 (0.74-0.79) for clopidogrel, 0.67 (0.59-0.77) for dipyridamole, 0.67 (0.53-0.86) for Aggrenox and 0.96 (0.90-1.03) for warfarin. The highest odds ratio for intracerebral hemorrhage was 5.33 (1.25-22.72) in younger patients using Aggrenox. The highest odds ratio for gastrointestinal bleeding was 1.34 (1.10-1.64) for clopidogrel. Conclusion Antiplatelet agents, but not warfarin, might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals because it might increase the rate of intracerebral hemorrhage.

2018-01-01·ANZ Journal of Surgery4区 · 医学

Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital

4区 · 医学

Article

作者: Papa, Nathan ; Clarke, Stephen ; Perera, Marlon ; Liodakis, Peter ; Lawrentschuk, Nathan ; Bolton, Damien M. ; Sengupta, Shomik ; Ow, Darren

BackgroundTo assess current treatment trends and perioperative outcomes of transurethral resection of the prostate (TURP) and photoselective vaporization of the prostate (PVP) in a tertiary institution.MethodsWe prospectively collected a database of all patients undergoing TURP and PVP for benign prostatic hyperplasia (BPH) at a tertiary hospital between January 2011 and December 2013. Patient characteristics such as length of stay, readmission, anticoagulation status, American Society of Anesthesiologists (ASA) score and need for blood transfusion were recorded and analysed.ResultsIn total, 560 cases were included: 204 (36.4%) underwent TURP and 356 (63.6%) PVP. Patients undergoing PVP had higher ASA scores (P < 0.001) and were more frequently on continuing anticoagulant therapy (P < 0.001). With regards to non‐aspirin/asasantin coagulation therapy, 61 (17.1%) patients underwent PVP with their anticoagulants continued while no patients who received TURP continued anticoagulation. Blood transfusion percentages were similar at 1.0% for TURP and 1.7% for PVP but readmission proportions were higher after PVP (32 patients, 9.0%) compared to TURP (10 patients, 4.9%). These differences were attenuated when excluding patients continuing anticoagulation during the procedure.ConclusionAt our institution, the use of PVP has been increasing on a year‐by‐year basis. The results of the current study demonstrated that PVP is safe in patients with increased anaesthetic risk or on active anticoagulation when compared to traditional TURP. While this makes PVP an attractive alternative to TURP in high‐risk anticoagulated patients, these patients may have complex post‐discharge issues that should be addressed during the informed consent process.

项与阿司匹林/双嘧达莫相关的新闻（医药）

2022-09-13

·国家药品监督管理局政务服务门户

2022年09月13日药品标准颁布件待领取信息发布

序号受理号药品名称批准日期1化补20220004愈美甲麻敏糖浆2022年09月07日2化修20220027参皇乳膏2022年09月07日3化修20220028阿司匹林双嘧达莫片2022年09月07日4化修20220029氟伐他汀钠胶囊2022年09月07日5化制20220006福多司坦片2022年09月07日6化制20220007福多司坦胶囊2022年09月07日7化制20220008福多司坦颗粒2022年09月07日8化制20220009福多司坦2022年09月07日9化制20220010氟伐他汀钠2022年09月07日

2022-04-26

·新浪医药新闻

恒瑞医药1类新药来袭剑指300亿抗栓药市场

4月25日，恒瑞公告表示，其子公司北京盛迪医药的1类新药SHR-2004注射液获批临床，拟用于预防或治疗动静脉血栓。数据显示，2020年中国公立医疗机构终端抗血栓形成药销售额超过300亿元，目前恒瑞已有3款抗血栓形成药获批上市，其中磺达肝癸钠注射液已拿下第七批集采入场券。据公告显示，SHR-2004注射液为大分子生物制剂，拟用于预防或治疗动静脉血栓，目前国内外尚无同类品种上市。截至目前，SHR-2004注射液相关项目累计已投入研发费用约2127万元。数据显示，除了SHR-2004注射液，恒瑞另一款1类抗血栓形成药SHR2285片已步入临床Ⅰ期阶段。目前恒瑞已上市的抗血栓形成药包括盐酸噻氯匹定片、磺达肝癸钠注射液以及阿司匹林双嘧达莫缓释胶囊3款。近年来，在支架国采的推动下，抗血栓形成药市场迎来增长新机。数据显示，2020年中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端抗血栓形成药销售额超过300亿元，受到疫情影响与往年相比稍稍下降，2021年上半年超过170亿元，同比增长13.89%。但头部市场主要由拜耳、赛诺菲以及勃林格殷格翰等海外企业所占据。目前利伐沙班片、阿哌沙班片、达比加群酯胶囊、硫酸氢氯吡格雷片、替格瑞洛片、注射用比伐芦定6款抗血栓形成药已被纳入集采，其中硫酸氢氯吡格雷片为首个被纳入国采的抗血栓形成药，赛诺菲、乐普、石药以及信立泰等企业中选。在即将开展的第七批集采中，磺达肝癸钠注射剂、替罗非班注射剂以及依替巴肽注射剂3款抗血栓形成药已被纳入集采范围，恒瑞的磺达肝癸钠注射剂已拿下入场券。内容来源于网络，如有侵权，请联系删除，谢谢。

2010-10-21

·Pharma Times

NICE launches database for referral advice

The National Institute for Health and Clinical Excellence has launched a database pulling together its recommendations on referring patients from primary to secondary care to improve outcomes and cut costs. The database will provide GPs with a one-stop-shop of guidance highlighting when patients could benefit from secondary care or specialist services, which, aside from securing better value for money and clinical outcomes, should help to improve the patient experience and reduce local and regional inequalities in care, the Institute said. Inappropriate referral to secondary care represents a significant and unnecessary cost to the NHS, and the database is one of a number of initiatives designed to help the health service deliver the QIPP (Quality, Improvement, Productivity and Prevention) agenda during a time of financial constraint. Professor Peter Littlejohns, NICE Clinical and Public Health Director said the new ‘referral advice’ recommendations database “is a valuable resource for those providing and commissioning care on when patients should be referred on from primary care”, which should help to ensure that patients receive treatment that is proven to be both clinically and cost effective. Final guidance for clopidogrel/dipyridamol Meanwhile, the cost watchdog has endorsed the wider use of clopidogrel as well as Boehringer Ingelheim’s modified-release dipyridamol for the prevention of occlusive vascular events. The Institute has OK’d funding for the wider use of clopidogrel (using the least costly preparation) in National Health Service patients who have had a stroke or who have peripheral arterial disease, and those who have cardiovascular disease in more than one area, to help prevent a subsequent heart attack or stroke. However, the drug is only recommended for patients who have had a heart attack if they are unable to take aspirin. A combination of modified-release dipyridamole - sold as Persantin Retard and Asasantin Retard by Boehringer - and aspirin is backed as an option for patients who have had a transient ischaemic attack, but should only be used when patients have had an ischaemic stroke where clopidogrel is contraindicated or not tolerated. The drug can also be used alone as an option following ischaemic stroke where aspirin and clopidogrel cannot be taken, the Institute said. Professor Peter Littlejohns, Clinical and Public Health Director at NICE, noted that heart attacks and strokes are some of the biggest killers and causes of disability the country, and that the new guidelines have “the potential to have a significant impact on the treatment of many thousands of patients in England and Wales”.

100 项与阿司匹林/双嘧达莫相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	阿司匹林/双嘧达莫	A01AD05 B01AC06 N02BA01	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
缺血性卒中	澳大利亚	Arrotex Pharmaceuticals Pty Ltd.初创企业	2014-05-09
短暂性脑缺血发作	加拿大	Boehringer Ingelheim GmbH	2000-04-17
脑梗塞	中国	德州博诚制药有限公司	1994-01-01
脑卒中	中国	Boehringer Ingelheim GmbH	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床2期	美国	Boehringer Ingelheim GmbH	2020-10-21
脑梗塞	临床2期	日本	Boehringer Ingelheim GmbH	2006-04-01
头痛	临床2期	中国台湾	Boehringer Ingelheim GmbH	2002-09-01
短暂性脑缺血发作	临床2期	美国	Boehringer Ingelheim Pharmaceuticals, Inc.	1999-11-22
缺血性卒中	临床2期	美国	Boehringer Ingelheim Pharmaceuticals, Inc.	1999-11-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01781611 (DARE, CTgov)	N/A	系统性红斑狼疮	18	extended release dipyridamole 200mg/aspirin 25mg (Extended Release Dipyridamole/Aspirin)	(壓構選觸築鹹淵壓鏇憲) = 淵選醖衊餘醖窪網壓製壓衊鹽繭願遞鹹蓋範築 (遞窪蓋廠觸鬱築鹹獵蓋, 膚觸鏇選製製齋壓衊願 ~ 範廠願蓋糧製夢窪範遞) 更多	-	2020-11-25
				81mg aspirin (Aspirin)	(壓構選觸築鹹淵壓鏇憲) = 醖壓獵襯觸鹽蓋襯觸壓壓衊鹽繭願遞鹹蓋範築 (遞窪蓋廠觸鬱築鹹獵蓋, 憲築衊構淵鏇鏇齋醖艱 ~ 夢簾觸鑰繭衊遞顧襯醖) 更多
ASN2018	N/A	透析血管通路衰竭	-	Aspirin	簾願艱遞鑰鹽廠網顧遞(憲憲醖鬱齋獵淵壓鑰觸) = 選夢餘範遞糧淵糧積衊窪膚齋憲範鬱餘憲壓齋 (窪獵顧願憲網醖觸淵壓, 0.10 ~ 0.28) 更多	积极	2018-10-23
				Clopidogrel	簾願艱遞鑰鹽廠網顧遞(憲憲醖鬱齋獵淵壓鑰觸) = 夢鬱範網壓憲憲襯襯構窪膚齋憲範鬱餘憲壓齋 (窪獵顧願憲網醖觸淵壓, 0.67 ~ 0.71) 更多
NCT00738894 (REDUCE, CTgov)	N/A	卵圆孔未闭 \| 脑卒中 \| 短暂性脑缺血发作	664	Septal Occluder Device+Plavix+Aggrenox+Clopidogrel+Dipyridamole+Aspirin (Device Closure)	艱鏇鏇鏇簾衊齋夢鏇衊(夢衊繭糧艱簾構廠網夢) = 範醖顧鹹衊醖願糧願夢膚餘廠廠壓遞簾範餘夢 (築餘鑰構簾鹽顧襯鏇壓, 鹹築簾齋壓簾簾淵鑰夢 ~ 鏇鬱襯餘積製積築繭顧) 更多	-	2018-08-09
				Plavix+Aggrenox+Clopidogrel+Dipyridamole+Aspirin (Medical Management)	艱鏇鏇鏇簾衊齋夢鏇衊(夢衊繭糧艱簾構廠網夢) = 積範鬱艱積膚憲積壓範膚餘廠廠壓遞簾範餘夢 (築餘鑰構簾鹽顧襯鏇壓, 鹽觸餘醖範積蓋範鹽餘 ~ 壓選醖膚夢鹹襯憲衊醖) 更多
NCT00906035 (CTgov)	N/A	外周动脉疾病	25	Aspirin 25mg bid: (Dipyridamole 200mg and Aspirin 25mg Bid)	憲醖淵鑰衊製艱網築顧(鹽範衊膚繭範鏇艱顧鏇) = 構壓積遞壓艱齋糧壓觸積願壓繭鏇艱獵鹽淵膚 (夢齋膚餘蓋廠廠繭鹽壓, 鹹蓋觸膚廠鹽選壓鬱範 ~ 糧衊獵齋築襯製襯鏇顧) 更多	-	2017-09-05
				Dipyridamole 200 mg bid (Dipyridamole 200 mg Bid)	憲醖淵鑰衊製艱網築顧(鹽範衊膚繭範鏇艱顧鏇) = 壓醖襯網積簾鹹鹹夢窪積願壓繭鏇艱獵鹽淵膚 (夢齋膚餘蓋廠廠繭鹽壓, 繭製艱夢觸築廠簾淵繭 ~ 鑰選窪膚醖築鑰網製網) 更多